Literature DB >> 1537076

Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

E Musch1, M Malek, J Peter-Katalinic, H Egge, H Rink, B Lathan, E Riedel.   

Abstract

Intracellular concentrations of prednimustine (PM), chlorambucil (CLB), phenylacetic acid mustard (PAAM) and prednisolone (P) were measured in different experimental tumor cell lines that had been incubated with either PM or CLB + P. For intracellular analytical determination, we modified a high-pressure liquid chromatographic method for the detection of these substances in plasma. Intact PM could be detected in the intracellular compartment of the incubated tumor cells. PM-incubated cells from PM-injected rats exhibited a higher intracellular concentration-time integral (PAAM) and longer concentration-time profiles for drugs with alkylating capacity than did cells exposed to the CLB + P mixture or to CLB. PAAM was not detectable after incubation of cells with PM, whereas in CLB-incubated cells the AUC of PAAM exceeded that of the parent drug CLB. Our in vitro results therefore favour the concept of a facilitated intracellular uptake and an increased antiproliferative effect for PM versus CLB and CLB + P.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537076     DOI: 10.1007/bf00685948

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  30 in total

1.  Studies on the toxicity and antitumour activity of prednimustine, a prednisolone ester of chlorambucil.

Authors:  K R Harrap; P G Riches; E D Gilby; S M Sellwood; R Wilkinson; I Konyves
Journal:  Eur J Cancer       Date:  1977-08       Impact factor: 9.162

2.  Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia.

Authors:  W H Knospe; V Loeb; C M Huguley
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

3.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.

Authors:  J Pedersen-Bjergaard; M M Hansen; C H Geisler; N I Nissen
Journal:  Acta Med Scand       Date:  1980

5.  Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

Authors:  D R Newell; A H Calvert; K R Harrap; T J McElwain
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

6.  Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group.

Authors:  D R Gandara; H G Wold; J Redmond; M Kohler; R Reynolds; P Wong; J Forsythe; K Fisher; B Lewis
Journal:  Semin Oncol       Date:  1986-03       Impact factor: 4.929

7.  The antitumor effect of prednimustine in vitro and in vivo.

Authors:  B Hartley-Asp
Journal:  Semin Oncol       Date:  1986-03       Impact factor: 4.929

8.  A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.

Authors:  J Løber; H T Mouridsen; I E Christiansen; P Dombernowsky; W Mattsson; M Rørth
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

9.  Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.

Authors:  F Y Lee; P Coe; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Prednimustine therapy for advanced prostatic cancer.

Authors:  R Catane; J H Kaufman; S Madajewicz; A Mittelman; G P Murphy
Journal:  Br J Urol       Date:  1978-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.